Form 4 for ARTV Artiva Biotherapeutics, Inc.

Accepted 2024-07-22 00:00:00 ET · period of report 2024-07-22 · accession 0001415889-24-019908 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-07-22	2024-07-22	ARTV	Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	10%	J - Other	$10.20	+49.0K	194.1K	+34%	+$500.0K
D	2024-07-22	2024-07-22	ARTV	Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	10%	C - Cnv Deriv	—	+145.1K	145.1K	New	—
D	2024-07-22	2024-07-22	ARTV	Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	10%	C - Cnv Deriv	—	-145.1K	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-07-22	J	A	49,019	$10.20	194,108	D	—	—
2	Common	Common Stock	2024-07-22	C	A	145,089	—	145,089	D	—	—	(F1) Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
3	Derivative	Series B Preferred Stock	2024-07-22	C	D	145,089	—	0	D	— · — to —	145,089 Common Stock	(F1) Each share of Series B Preferred Stock converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.